Decreased expression of thyroid peroxidase (TPO) is frequently observed in thyroid cancer, but the underlying regulatory mechanism remains largely unknown. This study aimed to elucidate the epigenetic basis of TPO silencing and assess its potential value for the diagnosis of thyroid cancer.
Methods:
DNA methylation and expression levels of TPO were analyzed using the Infinium HumanMethylation450 array and transcriptome data from The Cancer Genome Atlas thyroid cancer dataset and validated in clinical tissue samples by bisulfite sequencing polymerase chain reaction (PCR) and quantitative PCR (qPCR). Thyroid cancer cell lines MDA-T41, KTC-1, CAL62, and TTA1 were treated with the demethylating drug decitabine and subjected to DNA methylation and mRNA expression analyses. Potential regulatory proteins were identified through DNA pull-down coupled with LC-MS/MS and validated by chromatin immunoprecipitation, luciferase reporter assay, and qPCR. A pyrosequencing assay was designed to quantify the methylation level of TPO.
Results:
TPO expression was markedly downregulated in thyroid cancer and showed a strong inverse correlation with DNA methylation level at TPO differentially methylated region (DMR). Treatment of thyroid cancer cells with decitabine induced significantly decreased methylation level of TPO DMR and increased expression of TPO. Mechanistic analyses demonstrated that DNA hypermethylation suppressed TPO expression by recruiting methyl-CpG binding domain protein 2 (MBD2). Moreover, a pyrosequencing-based method for quantifying TPO methylation level was developed, and a remarkable difference between malignant and benign thyroid nodules (BTNs) was observed. Two CpG sites within TPO DMR achieved diagnostic performance with areas under the receiver operating characteristic curves of 0.927 (95% confidence interval [CI]: 0.864–0.989) and 0.916 (95% CI: 0.846–0.987), respectively.
Conclusions:
DNA hypermethylation suppresses TPO transcription by recruiting MBD2 in thyroid cancer. Quantitative assessment of TPO methylation by pyrosequencing offers a promising molecular diagnostic approach to distinguish malignant cancer from BTN. Further studies are warranted to ascertain the clinical diagnostic utility of these findings.
BrayF, LaversanneM, SungH, et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2024;74(3):229–263; doi: 10.3322/caac.21834
2.
BoucaiL, ZafereoM, CabanillasME. Thyroid cancer: A review. JAMA2024;331(5):425–435; doi: 10.1001/jama.2023.26348
3.
Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell2014;159(3):676–690; doi: 10.1016/j.cell.2014.09.050
4.
WangJR, ZafereoME, CabanillasME, et al.The association between thyroid differentiation score and survival outcomes in papillary thyroid carcinoma. J Clin Endocrinol Metab2025;110(2):356–363; doi: 10.1210/clinem/dgae532
5.
RufJ, CarayonP. Structural and functional aspects of thyroid peroxidase. Arch Biochem Biophys2006;445(2):269–277; doi: 10.1016/j.abb.2005.06.023
6.
ChungJK. Sodium iodide symporter: Its role in nuclear medicine. J Nucl Med2002;43(9):1188–1200.
7.
HouP, BojdaniE, XingM. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab2010;95(2):820–828; doi: 10.1210/jc.2009-1888
8.
SpitzwegC, BibleKC, HofbauerLC, et al.Advanced radioiodine-refractory differentiated thyroid cancer: The sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol2014;2(10):830–842; doi: 10.1016/S2213-8587(14)70051-8
9.
BuffetC, WassermannJ, HechtF, et al.Redifferentiation of radioiodine-refractory thyroid cancers. Endocr Relat Cancer2020;27(5):R113–R132; doi: 10.1530/ERC-19-0491
10.
LiangJ, CaiW, FengD, et al.Genetic landscape of papillary thyroid carcinoma in the Chinese population. J Pathol2018;244(2):215–226; doi: 10.1002/path.5005
11.
LandaI, IbrahimpasicT, BoucaiL, et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest2016;126(3):1052–1066; doi: 10.1172/JCI85271
12.
ZengPYF, ProkopecSD, LaiSY, et al.The genomic and evolutionary landscapes of anaplastic thyroid carcinoma. Cell Rep2024;43(3):113826; doi: 10.1016/j.celrep.2024.113826
13.
DuranteC, PuxedduE, FerrettiE, et al.BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab2007;92(7):2840–2843; doi: 10.1210/jc.2006-2707
14.
LiuJ, LiuR, ShenX, et al.The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. J Nucl Med2020;61(2):177–182; doi: 10.2967/jnumed.119.227652
15.
LiuD, HuS, HouP, et al.Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res2007;13(4):1341–1349; doi: 10.1158/1078-0432.CCR-06-1753
16.
ChakravartyD, SantosE, RyderM, et al.Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest2011;121(12):4700–4711; doi: 10.1172/JCI46382
17.
HoAL, GrewalRK, LeboeufR, et al.Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med2013;368(7):623–632; doi: 10.1056/NEJMoa1209288
18.
NagarajahJ, LeM, KnaufJA, et al.Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin Invest2016;126(11):4119–4124; doi: 10.1172/JCI89067
19.
DunnLA, ShermanEJ, BaxiSS, et al.Vemurafenib redifferentiation of BRAF mutant, RAI-Refractory thyroid cancers. J Clin Endocrinol Metab2019;104(5):1417–1428; doi: 10.1210/jc.2018-01478
20.
GreenbergMVC, Bourc’hisD. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol2019;20(10):590–607; doi: 10.1038/s41580-019-0159-6
21.
XingM, UsadelH, CohenY, et al.Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: A marker of malignancy and a cause of gene silencing. Cancer Res2003;63(9):2316–2321.
22.
GalraoAL, CamargoRY, FrigugliettiCU, et al.Hypermethylation of a New Distal Sodium/Iodide Symporter (NIS) Enhancer (NDE) is associated with reduced NIS expression in thyroid tumors. J Clin Endocrinol Metab2014;99(6):E944–E952; doi: 10.1210/jc.2013-1450
23.
ChoiYW, KimHJ, KimYH, et al.B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1. Exp Mol Med2014;46(11):e120; doi: 10.1038/emm.2014.68
24.
KartalK, OnderS, KosemehmetogluK, et al.Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material. BMC Cancer2015;15:824; doi: 10.1186/s12885-015-1861-1
25.
CapperD, JonesDTW, SillM, et al.DNA methylation-based classification of central nervous system tumours. Nature2018;555(7697):469–474; doi: 10.1038/nature26000
26.
OrozcoJIJ, KnijnenburgTA, Manughian-PeterAO, et al.Epigenetic profiling for the molecular classification of metastatic brain tumors. Nat Commun2018;9(1):4627; doi: 10.1038/s41467-018-06715-y
27.
YasuiK, ToshimaT, InadaR, et al.Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles. Mol Cancer2024;23(1):1; doi: 10.1186/s12943-023-01910-y
28.
TuttleRM, HaugenB, PerrierND. Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth Edition): What changed and why? Thyroid2017;27(6):751–756; doi: 10.1089/thy.2017.0102
29.
RingelMD, SosaJA, BalochZ, et al.2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer. Thyroid2025;35(8):841–985; doi: 10.1177/10507256251363120
30.
GodlewskaM, BangaPJ. Thyroid peroxidase as a dual active site enzyme: Focus on biosynthesis, hormonogenesis and thyroid disorders of autoimmunity and cancer. Biochimie2019;160:34–45; doi: 10.1016/j.biochi.2019.02.003
31.
MondalS, RajaK, SchweizerU, et al.Chemistry and biology in the biosynthesis and action of thyroid hormones. Angew Chem Int Ed Engl2016;55(27):7606–7630; doi: 10.1002/anie.201601116
32.
DriessensN, VersteyheS, GhaddhabC, et al.Hydrogen peroxide induces DNA single- and double-strand breaks in thyroid cells and is therefore a potential mutagen for this organ. Endocr Relat Cancer2009;16(3):845–856; doi: 10.1677/ERC-09-0020
33.
SinghE, GuptaA, SinghP, et al.Exploring mammalian heme peroxidases: A comprehensive review on the structure and function of myeloperoxidase, lactoperoxidase, eosinophil peroxidase, thyroid peroxidase and peroxidasin. Arch Biochem Biophys2024;761:110155; doi: 10.1016/j.abb.2024.110155
34.
ArczewskaKD, SysD, NilsenHL, et al.DNA damage and repair in thyroid physiology and disease. Endocr Rev2026;47(1):121–157; doi: 10.1210/endrev/bnaf035
35.
MuzzaM, PogliaghiG, ColomboC, et al.Oxidative stress correlates with more aggressive features in thyroid cancer. Cancers (Basel)2022;14(23):5857; doi: 10.3390/cancers14235857
36.
NilssonJN, SiikanenJ, CondelloV, et al.Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up. Eur Thyroid J2023;12(4):e230099; doi: 10.1530/ETJ-23-0099
37.
LiX, ChengR. TPO as an indicator of lymph node metastasis and recurrence in papillary thyroid carcinoma. Sci Rep2023;13(1):10848; doi: 10.1038/s41598-023-37932-1
38.
BaubecT, IvanekR, LienertF, et al.Methylation-dependent and -independent genomic targeting principles of the MBD protein family. Cell2013;153(2):480–492; doi: 10.1016/j.cell.2013.03.011
39.
WeiH, ZhengH, WangS, et al.Targeting redox-sensitive MBD2-NuRD condensate in cancer cells. Nat Cell Biol2025;27(5):801–816; doi: 10.1038/s41556-025-01657-2
40.
Abisoye-OgunniyanA, LinH, GhebremedhinA, et al.Transcriptional repressor Kaiso promotes epithelial to mesenchymal transition and metastasis in prostate cancer through direct regulation of miR-200c. Cancer Lett2018;431:1–10; doi: 10.1016/j.canlet.2018.04.044
41.
SasaiN, NakaoM, DefossezPA. Sequence-specific recognition of methylated DNA by human zinc-finger proteins. Nucleic Acids Res2010;38(15):5015–5022; doi: 10.1093/nar/gkq280
42.
ChenX, HuangMF, FanDM, et al.CARM1 hypermethylates the NuRD chromatin remodeling complex to promote cell cycle gene expression and breast cancer development. Nucleic Acids Res2024;52(12):6811–6829; doi: 10.1093/nar/gkae329
43.
SmithZD, HetzelS, MeissnerA. DNA methylation in mammalian development and disease. Nat Rev Genet2025;26(1):7–30; doi: 10.1038/s41576-024-00760-8
44.
Sharifi TabarM, GiardinaC, FengY, et al.Unique protein interaction networks define the chromatin remodelling module of the NuRD complex. Febs J2022;289(1):199–214; doi: 10.1111/febs.16112
45.
SizemoreGM, PitarresiJR, BalakrishnanS, et al.The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer2017;17(6):337–351; doi: 10.1038/nrc.2017.20
46.
ZafonC, GilJ, Perez-GonzalezB, et al.DNA methylation in thyroid cancer. Endocr Relat Cancer2019;26(7):R415–R439; doi: 10.1530/ERC-19-0093
47.
XiaoX, ChenM, SangY, et al.Methylation-Mediated silencing of ATF3 promotes thyroid cancer progression by regulating prognostic genes in the MAPK and PI3K/AKT pathways. Thyroid2023;33(12):1441–1454; doi: 10.1089/thy.2023.0157
48.
LiS, XueJ, JiangK, et al.TERT promoter methylation is associated with high expression of TERT and poor prognosis in papillary thyroid cancer. Front Oncol2024;14:1325345; doi: 10.3389/fonc.2024.1325345
49.
LiS, HuG, ChenY, et al.TERT upstream promoter methylation regulates TERT expression and acts as a therapeutic target in TERT promoter mutation-negative thyroid cancer. Cancer Cell Int2024;24(1):271; doi: 10.1186/s12935-024-03459-2
